Trial reportHaematologica2019
Disability related to chronic graft -
Open access · goldAbstract readClinical Trial
In one paragraph
Trial report in Haematologica, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 32 citations in OpenAlex.
- Novel highly selective ROCK2 inhibitor (TDI01) for the treatment of chronic graft-versus-host disease: a multicenter, open-label phase Ib/II study.Signal transduction and targeted therapy · 2026Trial
- Group Coping Intervention in Patients With Chronic Graft-Versus-Host Disease: A Pilot Randomized Clinical Trial.Journal of the National Comprehensive Cancer Network : JNCCN · 2024Trial
- Cord blood transfusion added matched unrelated donor transplantation as a preferable choice for aplastic anaemia: a comparative study from a single centre.Annals of medicine · 2026Article
- Chronic graft-versus-host disease after PTCy-based prophylaxis vs non-PTCy prophylaxis.Blood advances · 2026Article
- Patient-reported outcomes in chronic GVHD: instruments, clinical utility, and survivorship integration.Journal of patient-reported outcomes · 2026Review
- Work Participation of Hematological Cancer Survivors After Hematopoietic Cell Transplantation: A Scoping Review.Journal of occupational rehabilitation · 2026Article
- GvHD prophylaxis with tacrolimus, sirolimus, and mycophenolate mofetil after reduced intensity conditioning hematopoietic stem cell allogeneic transplantation.Bone marrow transplantation · 2025Article
- Development of the Lee Symptom Scale-Skin Sclerosis for chronic GVHD-associated sclerosis.Blood · 2025Article
- Impact of stem cell source on secondary steroid for chronic GVHD after allogeneic hematopoietic cell transplantation.International journal of hematology · 2025Article
- Article
- Review
- Disability Associated with Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation: Analysis of a Cross-Sectional US Patient Survey.Oncology and therapy · 2024Article
- [Evaluation of differences in quality of life in patients with chronic graft-versus-host disease].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2024Article
- Incidence and predictors of recurrent sick leave in survivors who returned to work after allogeneic hematopoietic cell transplantation.Journal of cancer survivorship : research and practice · 2023Article
- Comparable survival outcomes with haploidentical stem cell transplantation and cord blood transplantation.Bone marrow transplantation · 2022Article
- Characteristics of Graft-Versus-Host Disease (GvHD) After Post-Transplantation Cyclophosphamide Versus Conventional GvHD Prophylaxis.Transplantation and cellular therapy · 2022Article
- Recommendations on service delivery to help reduce suffering and anxiety in patients and caregivers post-hematopoietic cell transplantation: a case report.Journal of medical case reports · 2021Article
- Frequent Eczematous Dermatitis in Unrelated Cord Blood Hematopoietic Cell Transplant Recipients Compared With Other Donor Types.Transplantation and cellular therapy · 2021Article
- Steroid-refractory chronic graft-versus-host disease: treatment options and patient management.Bone marrow transplantation · 2021Review
- National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2020 Etiology and Prevention Working Group Report.Transplantation and cellular therapy · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 2 countries.
Giancarlo FatobeneFred Hutchinson Cancer Research Center, Clinical Research Division, Seattle, WA, USA.
Barry E StorerFred Hutchinson Cancer Research Center, Clinical Research Division, Seattle, WA, USA.
Rachel B SalitFred Hutchinson Cancer Research Center, Clinical Research Division, Seattle, WA, USA.
Stephanie J LeeFred Hutchinson Cancer Research Center, Clinical Research Division, Seattle, WA, USA.
Paul J MartinFred Hutchinson Cancer Research Center, Clinical Research Division, Seattle, WA, USA.
Guang-Shing ChengFred Hutchinson Cancer Research Center, Clinical Research Division, Seattle, WA, USA.
Paul A CarpenterFred Hutchinson Cancer Research Center, Clinical Research Division, Seattle, WA, USA.
Gansuvd BalgansurenUniversity of Washington, Division of Medical Oncology, Seattle, WA, USA.
Effie W PetersdorfFred Hutchinson Cancer Research Center, Clinical Research Division, Seattle, WA, USA.
Colleen DelaneyFred Hutchinson Cancer Research Center, Clinical Research Division, Seattle, WA, USA.
Brenda M SandmaierFred Hutchinson Cancer Research Center, Clinical Research Division, Seattle, WA, USA.
Filippo MilanoFred Hutchinson Cancer Research Center, Clinical Research Division, Seattle, WA, USA.
Mary E FlowersFred Hutchinson Cancer Research Center, Clinical Research Division, Seattle, WA, USA mflowers@fhcrc.org.
Fred Hutch Cancer Center · USUniversity of Washington Medical Center · US
Funding
Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Eric Collisson · 1985 to 2026
$296.4MVIRUS-MEDIATED MYELOSUPPRESSIONP01CA018029 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI STEPHANIE J LEE · 1985 to 2026
$128.4MProject 3: Gene Therapy for Correction of Blood DisordersP01HL122173 · NHLBI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI KIEM, HANS-PETER · 2015 to 2019
$12.9MImproving Outcomes Assessment in Chronic GVHDR01CA118953 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI LEE, STEPHANIE J · 2011 to 2025
$8.3MImproving Outcomes Assessment in Chronic GVHDU01CA118953 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI LEE, STEPHANIE J · 2007 to 2010
$3.1MNCI NIH HHS P01 CA018029NCI NIH HHS P30 CA015704NCI NIH HHS R01 CA118953NCI NIH HHS U01 CA118953NHLBI NIH HHS P01 HL122173
Abstract
We determined the incidence of disability related to chronic graft-
Indexed as
Cord Blood Stem Cell TransplantationGraft vs Host DiseaseHistocompatibility TestingPeripheral Blood Stem Cell TransplantationUnrelated DonorsAdolescentAdultAgedDisease-Free SurvivalFemaleHLA AntigensHumansMaleMiddle AgedRetrospective StudiesSurvival RateHLA Antigens
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.